Kailera Therapeutics, Inc.
KLRA · Pharmaceutical Preparations
Latest available SEC filing: 10-Q ·
Latest disclosures
-
Latest financial period: Q3 2026
Financial facts · Filed
-
Form 10-Q
SEC filing · Filed
-
Nicholson Nur: Form 4
Insider disclosure · Filed · Report period 07 Sep 2026
-
Form 3
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 3
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- KLRA · 482931102 - Common Stock, $0.00001 par value
Company details and SEC sources
CIK 0002096997 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- KLRA on Nasdaq
- SEC industry group
- Pharmaceutical Preparations (Office of Life Sciences)
- Business address
- 180 Third Avenue, 4 Th Floor, Waltham, MA, 02451
- Incorporated in
- DE
- Fiscal year end
- 31 December
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields